Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial aetiology. Here we study associations between A subset of 5638 interferon-beta (IFNβ)-treated and 3440 natalizumab-treated patients having data on at least the first two years of treatment were eligible for interval-censored time-to-event analysis.
Patients older than 50 years at start of IFNβ therapy developed ADA more frequently than adult patients younger than 30 (pooled HR = 1.8, 95% CI 1.4-2.3).
Men developed ADA more frequently than women (pooled HR = 1.3, 95% CI 1.1-1.6).
Interestingly we observed that in Sweden and Germany, patients who started IFNβ in April were at higher risk of developing ADA (HR = 1.6, 95% CI 1.1-2.4 and HR = 2.4, 95% CI 1.5-3.9 respectively).
Is this the month of treatment effect and it is all to do with vitamin D or does this show if you do enough comparisons one or two will show a difference.
This result is not confirmed in the other cohorts and warrants further investigations….. Does it Really?:-)
Concerning natalizumab, patients older than 45 years had a higher ADA rate (pooled HR = 1.4, 95% CI 1.0-1.8) and women developed ADA more frequently than men (pooled HR = 1.4, 95% CI 1.0-2.0).
So says the same as the beta interferon results so more reason to start therapy in your youth.
We confirmed previously reported differences in immunogenicity of the different types of IFNβ.
Differences in ADA occurrence by sex and age are reported here for the first time. These findings should be further investigated taking into account other exposures and biomarkers.
So neutralizing antibodies are a problem for drugs and if they occur the drugs can stop working.
The occurrence of neutralising antibodies varies from agent to agent for the interferons it may be about 30% for natalizumab its about 6%….what happens with alemtuzumab where it occurs in 80% of people?…..Yes about 80% of people